Literature DB >> 7180452

Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.

M Szaff, N Høiby.   

Abstract

During the period 1965-79 191 cystic fibrosis patients have been treated with 2349 course of anti-staphylococcal chemotherapy in the Danish Cystic Fibrosis Centre. The standard treatment was orally administered Fusidic acid in combination with Oxacillin or Dicloxacillin given for 14 days. In cases of penicillin allergy Fusidic acid in combination with Rifampicin was given. The overall results showed that S. aureus was eradicated from sputum by a single course of chemotherapy in 74% of the cases, although in 8% the original strains (phage-type) was replaced by a new strain. Repeated or extended treatment was successful in most of the remaining cases and, as a result, only 9% of our patients harboured S. aureus continuously for 6 months or more. On the average each patient received 2 anti-staphylococcal treatment per year, but no decrease in efficacy of repeated treatment was seen. Likewise, no significant increase of S. aureus precipitins and no development of resistant strains was seen in our patients. Due to the efficacy of chemotherapy and the principles of early treatment whether there are clinical symptoms of infection or not, S. aureus infection is now considered a minor problem without relation to poor prognosis in our cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180452     DOI: 10.1111/j.1651-2227.1982.tb09526.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  17 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

Review 2.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 3.  Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.

Authors:  K McCaffery; R E Olver; M Franklin; S Mukhopadhyay
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

4.  Prospective study of serum staphylococcal antibodies in cystic fibrosis.

Authors:  A E Hollsing; M Granström; B Strandvik
Journal:  Arch Dis Child       Date:  1987-09       Impact factor: 3.791

5.  Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.

Authors:  C Koch; N Høiby
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

6.  Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

Authors:  T Jensen; S S Pedersen; N Høiby; C Koch
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

7.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 8.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 9.  Cystic fibrosis. 2. Lung injury in cystic fibrosis.

Authors:  J S Elborn; D J Shale
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

10.  Newborn Cystic Fibrosis Pigs Have a Blunted Early Response to an Inflammatory Stimulus.

Authors:  Jennifer A Bartlett; Shyam Ramachandran; Christine L Wohlford-Lenane; Carrie K Barker; Alejandro A Pezzulo; Joseph Zabner; Michael J Welsh; David K Meyerholz; David A Stoltz; Paul B McCray
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.